Akari Therapeutics PLC (NASDAQ:AKTX) stock is experiencing a price correction on Tuesday. The decline follows an extraordinary 255% surge late last week.
Preclinical Data Sparks Momentum
Something went wrong.
Akari stock traded higher on Friday on promising preclinical data. The company revealed that its asset, AKTX-101, produced synergistic activity alongside KRAS inhibition in KRAS-mutated pancreatic cancer models. Specifically, combining AKTX-101 with the KRAS inhibitor adagrasib produced strong synergistic cell-killing activity in cell lines driven by KRAS G12D and KRAS G12C mutations.
Payload Synergy
